

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45251

Title: Sofosbuvir/Ribavirin therapy for Patients Experiencing Failure of Ombitasvir/Paritaprevir/Ritonavir+Ribavirin therapy: Two cases report

Reviewer's code: 03010025

Reviewer's country: Iraq

Science editor: Ying Dou

Date sent for review: 2019-01-09

Date reviewed: 2019-01-09

Review time: 2 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input checked="" type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This paper reports effectiveness of sofosbuvir/ribavirin (SOF/RBV) therapy in patients who experienced failure of ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r+RBV) therapy and had HCV genotype 2. The paper is well written. I



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

have no further comments.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 45251

Title: Sofosbuvir/Ribavirin therapy for Patients Experiencing Failure of Ombitasvir/Paritaprevir/Ritonavir+Ribavirin therapy: Two cases report

Reviewer's code: 04072104

Reviewer's country: Japan

Science editor: Ying Dou

Date sent for review: 2019-01-09

Date reviewed: 2019-01-14

Review time: 18 Hours, 4 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This case reports are written well. Host cytokines and the innate immune responses linked to adaptive immune responses play an important role in regulating HCV. Not only viral factors but also host factors associated with mechanism of nonresponse to



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

antivirals should be described. Factors possibly affecting SVR 12 should be described including degree of fibrosis (Fib 4 index, APRI score), alpha-fetoprotein, pathological examination by liver biopsy and portosystemic shunts. In patient 2 with chronic hepatitis C with high viral loads and genotype 2a and RA, reactivation of hepatitis C virus and hepatitis B virus during and after treatment for RA, results of anti-MMP antibody, anti CCP antibody, antinuclear antibody, IgG, complements and C-reactive protein should be showed.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No